Business
Gear International Funds Cannaworx Partnership With Innovative Extractions to Develop Proprietary Cannabis and Hemp Based Products
Gear International Funds Cannaworx Partnership With Innovative Extractions to Develop Proprietary Cannabis and Hemp Based Products.
About this update from Matchaah Holdings Inc
[{"type":"text","content":"\n \n \n Gear International Funds Cannaworx Partnership With Innovative Extractions to Develop Proprietary Cannabis and Hemp Based Products\n \n \nGear International Funds Cannaworx Partnership With Innovative Extractions to Develop Proprietary Cannabis and Hemp Based Products\n\nThese \"Cannabinoid-Specific\" Formulas Will Serve Specific Patient Needs by Addressing the Primary Symptoms Associated With Them\n\n \n PENSACOLA, FL--(Marketwired - Sep 14, 2015) - Gear International, Inc. (OTC PINK: GEAR) is pleased to announce that Cannaworx, a GEAR portfolio company, has partnered with Innovative Extractions to acquire cutting edge extraction systems in order to develop proprietary cannabis and hemp based products. The new system allows for the extraction of multiple plant materials concurrently while keeping the outputs isolated. These \"cannabinoid-specific\" formulas will serve specific patient needs more effectively by addressing the primary symptoms associated with them.\n \"While Cannaworx does not claim cannabis to be a cure for cancer and the many other health challenges of our day, we can provide patient testimony and actual evidence that cannabis has helped other groups of patients with the same conditions,\" said Robert F. Calkin, CEO of Cannaworx, Inc. \"We will be conducting efficacy and safety trials in tandem with doctors in multiple areas of medicine who all have separate concerns and necessary outcomes in mind. We intend to modify these formulas to the needs of these patient groups in hopes that we will be able to help them more effectively and provide a way for their formulas to be produced.\" \n New Terpene and Cannabinoid Arrays\n Dr. Gerry Bedore from Cannaworx works directly with these patients every day, observing the results of cannabinoid therapy. \"Based on patient response trials, specific cannabinoid and terpene arrays have reduced the need for opioids in pain management for severely ill patients, giving the patients improved sleep, improved appetites, and improved mental dispositions at a minimum. An improved quality of life is the worst case response we are seeing. In the best case scenarios, we are seeing patients being healed from many other deadly diseases. It is time for America to flip the switches and allow our medical communities to research and work with cannabinoids.\"\n The list of conditions...